Chen C - Search Results

1

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. Patnaik A, et al. Among authors: chen c. Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14. Clin Cancer Res. 2015. PMID: 25977344 Clinical Trial.

2

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.

Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Krop I, et al. Among authors: chen c. J Clin Oncol. 2012 Jul 1;30(19):2307-13. doi: 10.1200/JCO.2011.39.1540. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547604 Clinical Trial.

3

A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.

Sun X, Li X, Chen C, Song Y. Sun X, et al. Among authors: chen c. J Biopharm Stat. 2013;23(5):986-1003. doi: 10.1080/10543406.2013.813524. J Biopharm Stat. 2013. PMID: 23957511

4

Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.

Li W, Chen C, Li X, Beckman RA. Li W, et al. Among authors: chen c. Stat Med. 2017 May 30;36(12):1843-1861. doi: 10.1002/sim.7272. Epub 2017 Mar 17. Stat Med. 2017. PMID: 28303586

5

Adaptive expansion of biomarker populations in phase 3 clinical trials.

Chen C, Li XN, Li W, Beckman RA. Chen C, et al. Contemp Clin Trials. 2018 Aug;71:181-185. doi: 10.1016/j.cct.2018.07.001. Epub 2018 Jul 5. Contemp Clin Trials. 2018. PMID: 29981858

6

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Wang M, Chen C, Jemielita T, Anderson J, Li XN, Hu C, Kang SP, Ibrahim N, Ebbinghaus S. Wang M, et al. Among authors: chen c. J Immunother Cancer. 2019 Feb 8;7(1):39. doi: 10.1186/s40425-019-0513-4. J Immunother Cancer. 2019. PMID: 30736858 Free PMC article. Clinical Trial.

7

Testing monotherapy and combination therapy in one trial with biomarker consideration.

Sun LZ, Kang SP, Chen C. Sun LZ, et al. Among authors: chen c. Contemp Clin Trials. 2019 Jul;82:53-59. doi: 10.1016/j.cct.2019.06.002. Epub 2019 Jun 12. Contemp Clin Trials. 2019. PMID: 31201949

8

Multi-stage enrichment and basket trial designs with population selection.

Li W, Zhao J, Li X, Chen C, Beckman RA. Li W, et al. Among authors: chen c. Stat Med. 2019 Dec 20;38(29):5470-5485. doi: 10.1002/sim.8371. Epub 2019 Oct 17. Stat Med. 2019. PMID: 31621949

9

Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.

Jemielita T, Li XN, Piperdi B, Zhou W, Burke T, Chen C. Jemielita T, et al. Among authors: chen c. JCO Clin Cancer Inform. 2021 Jan;5:56-65. doi: 10.1200/CCI.20.00099. JCO Clin Cancer Inform. 2021. PMID: 33439727 Free article. Clinical Trial.

10

Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.

Sun LZ, Wu C, Li X, Chen C, Schmidt EV. Sun LZ, et al. Among authors: chen c. Contemp Clin Trials. 2021 Jul;106:106434. doi: 10.1016/j.cct.2021.106434. Epub 2021 May 15. Contemp Clin Trials. 2021. PMID: 34004341

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90,495 results

Search Page

Filters